Spruce biosciences reports second quarter 2025 financial results and provides corporate updates

South san francisco, calif.--(business wire)--spruce biosciences, inc. (otcqb: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended june 30, 2025 and provided corporate updates. “we remain steadfast in our efforts to advance ta-ert as a potential first-to-market treatment for children diagnosed with sanfilippo syndrome t.
SPRB Ratings Summary
SPRB Quant Ranking